Castle Creek Biosciences Announces $75 Million Investment to Advance Development of Multiple Gene Therapy Candidates for Rare Diseases
March 25, 2020 08:00 ET
|
Castle Creek Biosciences
- Leveraging proprietary technology and manufacturing platform to develop transformative gene therapies for multiple rare diseases with high unmet needs - - Pipeline led by Phase 3 gene...
Castle Creek Pharmaceutical Holdings to Acquire Fibrocell
September 12, 2019 17:40 ET
|
Fibrocell Science Inc.
- Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle...
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
August 14, 2019 16:45 ET
|
Fibrocell Science Inc.
- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy...
Fibrocell to Present at BIO International Convention 2019
May 30, 2019 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
May 29, 2019 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
May 15, 2019 07:30 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
May 09, 2019 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
April 15, 2019 06:30 ET
|
Fibrocell Science Inc.
- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and a 30% gross profit share - - Fibrocell retains rights to the eligible Rare...
Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
April 03, 2019 08:00 ET
|
Fibrocell Science Inc.
- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts - EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene...
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
March 27, 2019 07:30 ET
|
Fibrocell Science Inc.
- Phase 3 clinical trial, named DEFI-RDEB, is expected to commence in the second quarter of 2019 - - Additional data from Phase 1/2 clinical trial demonstrates FCX-007 continues to be well...